Anacor Pharmaceutical
About:
Anacor Pharmaceutical is a biopharmaceutical company developing small-molecule therapeutics from its boron chemistry platform.
Website: http://www.anacor.com
Top Investors: Hercules Capital, Venrock, Rho Capital Partners, GSK, Aberdare Ventures
Description:
Anacor Pharmaceuticals is a biopharmaceutical company that engages in developing small-molecule therapeutics from its boron chemistry platform. It focuses on developing topical applications of its compounds to treat fungal, bacterial, and inflammatory diseases. The company’s primary product candidate, AN2690, is a novel topical antifungal for the treatment of toenail onychomycosis, a fungal infection of the nail and nail bed. It is also developing AN2728, an anti-inflammatory product candidate for the treatment of psoriasis; AN0128, a product candidate that has antibiotic and anti-inflammatory properties; and AN2718, which is in preclinical development for the topical treatment of vaginal candidiasis and tineapedis.
$448M
$50M to $100M
Palo Alto, California, United States
2000-01-01
info(AT)anacor.com
Lucy Shapiro, Stephen Benkovic
51-100
2016-04-06
Delisted
© 2025 bioDAO.ai